Johnson & Johnson to Acquire Atraverse Medical to Complete Electrophysiology Workflow with Hotwire Transseptal Access System

Apr 25, 2026 17:24 CST Updated 17:24

Johnson & Johnson

Medical Device R&D and Manufacturer

Atraverse Medical

Left Heart Passage Device Developer

Instrument Family

Pioneer in Medical Device Media Reports

Share Professional Medical Device Knowledge

Source:Instrument Family,Reprint is prohibited without authorization, and can only be reprinted 24 hours later.

April 24,Johnson & Johnson Officially Announces Final Acquisition Agreement with Innovative Medical Device Company Atraverse Medical, planning to incorporate the latter into its medical technology division.

Data shows,Atraverse Medical is an innovative company focused on the research and development of cardiac interventional access devices.Founded jointly by Steven Mickelsen, who is acclaimed as the "Father of PFA," along with Eric Sauter and John Slump,Its core product, the Hotwire Transseptal Access System, has been applied in nearly 3,000 clinical surgeries.

From an industry perspective, this acquisition is not only another precise layout by Johnson & Johnson in the cardiac ablation field but also reflects the deep logic of global medtech giants building full-industry-chain barriers and seizing high-growth tracks through mergers and acquisitions. Reportedly, this acquisition is expected to close in the second quarter of 2026, with specific financial terms yet undisclosed.

Another Major Acquisition

Complete the Entire Electrophysiology Chain

The core value of this acquisition lies in filling a crucial "access link" for Johnson & Johnson’s existing cardiac ablation solutions, achieving a complete clinical closed loop from mapping, access creation to ablation therapy.

According to the official announcement from Johnson & Johnson, Atraverse Medical is headquartered in San Diego, USA.Its core product HotwireTransseptal Access System, an innovative left-heart interventional device that integrates a radiofrequency guidewire with a radiofrequency generator, specifically designed for minimally invasive ablation procedures for arrhythmias such as atrial fibrillation.

Currently, the system has received dual FDA certifications: In May 2024, the Hotwire RF guidewire was first approved; in December 2025, the accompanying RF generator completed its second certification, marking the full commercial rollout of the system. As of the release of the acquisition announcement, the Hotwire system had been successfully applied in over 3,000 clinical surgeries worldwide, with positive clinical data reported.

Hotwire Transseptal Access System

In atrial fibrillation ablation procedures, safely and accurately establishing access to the left atrium is a core factor determining the success and efficiency of the surgery, as well as a long-standing challenge in clinical practice. Traditional transseptal puncture relies on step-by-step operations using a puncture needle and guidewire, presenting issues such as cumbersome instrument changes, imprecise energy control, and higher puncture risks.

The core breakthrough of the Hotwire system lies in establishing a left-heart access pathway without the need for instrument changes. The guidewire can directly complete the puncture and serve as the operational track for subsequent catheter-based treatments, significantly streamlining the surgical process.Its technical highlights are concentrated in three core advantages:

• Intelligent Safety Control, with built-in impedance sensing automatic power-off function, accurately monitors the puncture status, prevents energy loss after left atrial puncture, and significantly reduces surgical risks;

• Precise Control Experience, an integrated RF generator can activate energy within the sterile field, combined with clear tip visualization under intracardiac echocardiography (ICE), providing operators with ultimate control precision;

• Wide Clinical Adaptability, compatible with all commercially available sheaths with an inner diameter of 0.032-0.038 inches, can be integrated into existing surgical procedures without the need for specialized equipment, reducing the learning curve for operators.

For Johnson & Johnson, the acquisition of Atraverse is not merely a simple product addition but a strategically precise move to fill a gap. Currently,Johnson & Johnson Medical Technologies already owns two core electrophysiology assets: the Carto 3 Three-Dimensional Mapping System and the Varipulse Pulsed Field Ablation Platform, which respectively occupy key stages in cardiac mapping and ablation therapy.

The addition of the Hotwire system,This will completely打通 the entire process chain of mapping, access, and ablation, giving Johnson & Johnson a unique closed-loop advantage in the globally high-growth field of atrial fibrillation ablation.As officially stated by Johnson & Johnson Medical Technologies, this acquisition will "further strengthen its cardiac ablation solutions portfolio" and consolidate its leadership position in the electrophysiology field.

Focus on Electrophysiology

The acquired party was founded by the "Father of PFA"

As the acquired party in this transaction, Atraverse Medical's core competitiveness also lies in its team's deep accumulation and successful entrepreneurial experience in the field of cardiac electrophysiology.

It is reported that,Atraverse Medical was founded in July 2022, and its founding team is a "star lineup" in the field of cardiac electrophysiology.The company was co-founded by Steven Mickelsen, Eric Sauter, and John Slump.Among them, Steven Mickelsen is a pioneer in the field of Pulsed Electric Field Ablation (PFA) and is hailed as the "Father of PFA."Previously, Farapulse, the company he co-founded with Eric Sauter, was acquired by Boston Scientific for up to $800 million in 2021, becoming a classic M&A case in the electrophysiology field.

CEO John Slump is a serial entrepreneur with three medical technology company acquisition exits under his belt, representing cumulative transaction value exceeding $1 billion. He possesses mature commercialization and team management capabilities. This team, which successfully developed and commercialized PFA technology in the past, has once again focused on the clinical pain point of transseptal access. They propelled the Hotwire system through FDA approval in just 22 months, demonstrating exceptional technical translation and clinical implementation abilities.

From the perspective of product layout,Atraverse Medical adopts a strategy of single-point breakthrough and extreme深耕, focusing on the细分赛道 of transseptal access devices without pursuing多元化扩张.Since its establishment, all R&D resources have been invested in the iterative optimization of the Hotwire system, from guidewire design and RF generator integration to clinical validation, forming a complete technical barrier.

June 2025,Atraverse Secures $29.4 Million in Series A Financing, Led by Mohan Growth Partners, The funds are mainly used for the global commercial promotion and clinical data accumulation of the Hotwire system. As of before the acquisition,The company has established partnerships with multiple top cardiac centers worldwide, with clinical data covering multi-center and multi-procedural scenarios, validating the safety and efficacy of the Hotwire system.`, laying a solid foundation for subsequent integration into the Johnson & Johnson commercialization system.`

Some analysts pointed out that Atraverse Medical’s three core values—technology, team, and clinical validation—are highly aligned with Johnson & Johnson Medical Technologies' acquisition preference for "focusing on highly innovative and high-growth early-stage targets," which became a key reason for the rapid completion of this transaction.

Johnson & Johnson Dual-Track M&A Strategy

Build a Full Cardiovascular Industry Chain

It is worth mentioning that,One of the most active acquirers in the global medical device industry, Johnson & JohnsonMedical TechnologySince focusing on core sectors and divesting its consumer health business in 2022,Invested over 30 billion US dollars in the medical fieldTherapy Technology M&A。Among them,The cardiovascular field has become one of the key focuses of its mergers and acquisitions.

From the perspective of mergers and acquisitions strategy,Johnson & Johnson's M&A follows a dual-track model of major strategic acquisitions and early-stage innovation reinforcement, with a core focus on the high-growth cardiovascular sector.In terms of major acquisitions, in 2022, Johnson & Johnson spent $16.6 billion to acquire Abiomed, filling the gap in severe heart failure treatment. In 2024, it spent $13.1 billion to bring Shockwave Medical under its wing, entering the field of vascular calcification treatment, while also acquiring companies such as V-Wave and Laminar to complete its product pipeline.

As a startup established just four years ago, Atraverse is a prime example of early-stage innovative reinforcement. Its technology is highly innovative and strategically synergistic, aligning perfectly with Johnson & Johnson's reinforcement-focused M&A strategy to quickly fill gaps in the product portfolio.

Previously,Johnson & Johnson Medical Technology has stated that all its merger and acquisition decisions must meet three core criteria: scientific alignment, strategic alignment, and financial alignment.This logic was fully embodied in the Atraverse acquisition case.

Nowadays,Johnson & Johnson has built up a comprehensive cardiovascular industry chain layout from electrophysiology to heart failure, vascular calcification, and structural heart disease through a series of mergers and acquisitions.Forming a four-way rivalry with Medtronic, Abbott, and Boston Scientific. In the electrophysiology sector, which boasts an annual growth rate of over 15%, Johnson & Johnson has established a significant leading advantage through its closed-loop solutions and is continuously reshaping the competitive landscape of the global cardiovascular medical device industry.

——

Looking at the global development trend of the medical device industry, the competition in the cardiovascular intervention track has moved from a single product competition toComprehensive Solutions and Clinical Full-Process EcosystemThe comprehensive competition phase.Johnson & Johnson’s Acquisition of Atraverse Medical Is Not Only a Tactical Enhancement but Also a Long-term Strategic Move for the Giant to Leverage Its Mature M&A System to Deeply Cultivate Niche Fields and Build Technological Barriers.

Against the backdrop of accelerating industry consolidation, continuously upgrading clinical needs, and the rapid iteration of innovative technologies, international medical device companies represented by Johnson & Johnson are refining their pipeline layouts through targeted mergers and acquisitions. By precisely addressing unmet clinical pain points and relying on the dual drivers of in-house R&D and acquisitions, they are steadily enhancing their product portfolios.

In the field of cardiac electrophysiology, the left-heart approach, as a key component of ablation procedures, will drive the standardization and minimally invasive advancements in industry diagnosis and treatment through its technical upgrades. With its financial resources, distribution channels, clinical resources, and mature integration capabilities, Johnson & Johnson is expected to leverage the Hotwire system to achieve synergistic product growth. In this regard, DeviceHome will continue to monitor developments.

END

GE Healthcare Global CEO Bets on Tianjin Again

Centennial Medical Giant, "China's First" Lands in Shanghai

Minimally Invasive's Bet: Surgical Robotics Company Completes Major Acquisition

Siemens Announces: Timeline for Healthcare Business Spin-off

Well-known Innovative Medical Device Company, Layoffs 16%

Beijing High-End Vascular Intervention Company Completes 200 Million Yuan Financing

For the First Time, Mindray Adjusts Its Business Segments

Global Dental "Top Leader" Undergoes Major Management Overhaul

750 Million, China's Leading Imaging Company Plans Acquisition

A New Era in Surgery Has Arrived, United Imaging Breaks Through with an Ecosystem

BusinessBusiness cooperation email: qxzj@landianyiliao.com